Inovio Pharmaceuticals (NASDAQ:INO) Releases Earnings Results, Misses Expectations By $0.04 EPS

Inovio Pharmaceuticals (NASDAQ:INO) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.04), RTT News reports. Inovio Pharmaceuticals had a negative net margin of 16,238.91% and a negative return on equity of 88.13%. The business had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.10 million. During the same period in the previous year, the firm earned ($1.56) EPS.

Inovio Pharmaceuticals Stock Performance

Shares of INO traded down $0.27 during midday trading on Friday, hitting $8.44. 470,920 shares of the company traded hands, compared to its average volume of 443,908. The firm has a 50 day moving average of $9.49 and a 200-day moving average of $10.84. Inovio Pharmaceuticals has a 52 week low of $3.89 and a 52 week high of $14.75. The stock has a market cap of $218.69 million, a price-to-earnings ratio of -2.63 and a beta of 0.89.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada cut their price objective on shares of Inovio Pharmaceuticals from $11.00 to $8.00 and set a “sector perform” rating for the company in a research report on Friday. HC Wainwright reaffirmed a “neutral” rating and issued a $15.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, July 15th. Finally, Stephens began coverage on shares of Inovio Pharmaceuticals in a report on Tuesday, May 14th. They issued an “overweight” rating and a $20.00 target price for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $47.00.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.